A Phase I/II Study of Intratumoral Injection of rhuFlt3L/CDX-301 and Poly-ICLC in Combination With Low-Dose Radiotherapy in Low-Grade B-cell Lymphomas
Phase of Trial: Phase I/II
Latest Information Update: 26 Sep 2016
At a glance
- Drugs FLT-3 ligand (Primary) ; Poly ICLC (Primary)
- Indications B cell lymphoma
- Focus Therapeutic Use
- 13 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Nov 2018.
- 13 Sep 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2018.
- 18 Apr 2016 Flow cytometry and mass cytometry data from selected patients were presented at the American Association for Cancer Research (AACR) Annual Meeting 2016, according to a Celldex Therapeutics media release.